News Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia Jan 20, 2026read more Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting May 14, 2025read more Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA May 8, 2025read more The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform Mar 31, 2025read more Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic Sep 25, 2024read more Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Sep 12, 2024read more Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting May 9, 2024read more Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Jul 7, 2022read more Genespire appoints Phillippe Mauberna as Chief Financial Officer Jul 13, 2021read more « Older Entries
Genespire announces that GENE202 has been granted Orphan Drug Designation by the FDA and EC for the treatment of methylmalonic acidemia Jan 20, 2026read more
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting May 14, 2025read more
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA May 8, 2025read more
The AstraZeneca acquisition of EsoBiotec – important validation for Genespire’s lentiviral vector platform Mar 31, 2025read more
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic Sep 25, 2024read more
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting May 9, 2024read more
